SUPN vs TECH · rev $661.8M vs P/E 65, rev $1.22B
Supernus Pharmaceuticals Inc (SUPN) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Supernus Pharmaceuticals Inc (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported SUPN revenue for 2024-12-31 was $661.8M. Net income was $73.9M. Revenue was up 8.9% from 2023-12-31 to 2024-12-31. SUPN currently screens at market cap $2.53B.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
SUPN currently screens at market cap $2.53B. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the SUPN and TECH stock pages for the full models.
Not investment advice.